Prestige Consumer Healthcare
PBH | NYSE
$48.00
+$1.81 (+3.92%)
At close: Nov 16, 2026, 4:00 PM ET
$48.00
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Prestige Consumer Healthcare Company Profile
Company profile explainedCompany Profile
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Key Executives
| Name | Position |
|---|---|
| Ronald Lombardi | Chairman, President & Chief Executive Officer |
| Christine Sacco | Chief Financial Officer & Chief Operating Officer |
| Adel Mekhail | Executive Vice President of Marketing & Sales |
| Dean Siegal | Director of Communications |
| Jose Luis Rosado | Senior Vice President of Quality & Regulatory Affairs |
| Philip David Terpolilli | Director of Investor Relations |
| William C. P'Pool | Senior Vice President, General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
| Jul 15, 2026 | 8-K | Current Report |
| Jul 09, 2026 | 8-K/A | [Amend] Current Report |
Prestige Consumer Healthcare
| Country | United States |
| IPO Date | Feb 10, 2005 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 890 |
| CEO | Ronald Lombardi |
Contact Details
660 White Plains Road Tarrytown,
New York 10591 United States
Stock Details
| Ticker Symbol | PBH |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001295947 |
| CUSIP Number | 74112D101 |
| ISIN Number | US74112D1019 |
| SIC Code | 2834 |
Recent News
- 9 days ago / marketbeat.comWhat Premium Brands (PBH) Said on Its Q3 Earnings Call
- 9 days ago / marketbeat.comPrestige Consumer Healthcare Q2 Earnings Call Highlights
- 9 days ago / seekingalpha.comPrestige Consumer Healthcare Inc. (PBH) Q2 2027 Earnings Call Transcript
- 12 days ago / zacks.comCompared to Estimates, Prestige Consumer Healthcare (PBH) Q2 Earnings: A Look at Key Metrics
- 12 days ago / globenewswire.comPrestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
- 13 days ago / businesswire.comAmylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
- 24 days ago / gurufocus.comPrestige Consumer Healthcare Inc (PBH) Shares Fall 3.4% -- What GF Score of 70 Tells Investors
- 1 month ago / zacks.comIs it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
- 1 month ago / globenewswire.comPrestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results
- 1 month ago / marketbeat.comAmylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Add to Watchlist
Select watchlists to add or remove PBH